Biolife Solutions director Amy DuRoss sells $140,574 in stock

In a recent transaction, Amy DuRoss, a director at BioLife Solutions Inc. (NASDAQ:BLFS), a company currently valued at $1.17 billion, sold a significant portion of her holdings in the company. According to InvestingPro data, BLFS stock has shown notable volatility, with a 40% return over the past year despite recent price fluctuations. According to a filing with the Securities and Exchange Commission, DuRoss sold 5,632 shares of common stock on March 14, 2025. The shares were sold at a weighted average price of $24.96, resulting in a total transaction value of approximately $140,574. This sale was conducted under a pre-established Rule 10b5-1 trading plan. InvestingPro analysis indicates the company maintains a "GOOD" overall financial health score, with liquid assets exceeding short-term obligations.

Following the sale, DuRoss’s direct ownership in BioLife Solutions stands at 23,811 shares. Additionally, DuRoss acquired 6,876 shares of restricted stock on March 18, 2025, as part of the company’s 2023 Performance Incentive Plan, which will fully vest on the first anniversary of the measurement date, January 2, 2025. For deeper insights into BLFS’s financial health and growth prospects, including 7 additional exclusive ProTips, visit InvestingPro.

In other recent news, BioLife Solutions announced its financial results for the fourth quarter and full year of 2024, reporting a total revenue of $22.7 million for the fourth quarter, exceeding analysts’ estimates of $21.3 million. The company posted a net loss of $2.0 million, or ($0.04) per share, which was smaller than the projected loss of $4.4 million. For the year 2024, BioLife reported total revenue of $82.3 million, excluding $37.7 million from discontinued operations, and a net loss of $11.4 million. The Cell Processing segment showed significant growth, with a 31% year-over-year increase in revenue to $20.3 million for the fourth quarter. Analysts from KeyBanc Capital Markets and H.C. Wainwright have expressed confidence in BioLife’s future, with KeyBanc maintaining an Overweight rating and a $33 target, while H.C. Wainwright raised the price target to $30, up from $27. Benchmark also reiterated a Buy rating with a $30 target, highlighting the company’s strong performance and optimistic outlook. Looking forward, BioLife anticipates 2025 revenue to range between $95.5 million and $99 million, with Cell Processing revenue expected to grow 18-21%. The company’s strategic divestitures and focus on its core business are seen as key factors in its continued growth and profitability.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.